<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We measured the concentration of CD33 antigen on the surface of cells in 315 bone marrow (BM) samples and 114 corresponding peripheral blood (PB) samples from patients with various <z:hpo ids='HP_0001909'>leukemias</z:hpo> (<z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>], <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> [<z:mp ids='MP_0005481'>CML</z:mp>], <z:hpo ids='HP_0005547'>myeloproliferative disorder</z:hpo> [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>] other than <z:mp ids='MP_0005481'>CML</z:mp>, <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>]) and from control subjects </plain></SENT>
<SENT sid="1" pm="."><plain>Overall CD33 intensity in total CD33+ cells was significantly higher in BM than in PB </plain></SENT>
<SENT sid="2" pm="."><plain>CD33 intensity in total BM CD33+ cells differed significantly with the type of disease </plain></SENT>
<SENT sid="3" pm="."><plain>The median number of CD33 molecules per cell was highest in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, followed by <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:mp ids='MP_0005481'>CML</z:mp>, and control subjects and lowest in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>When only CD34+/CD33+ cells were examined, CD33 molecules per cell were highest in CD34+ cells in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and lowest in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e> (P = .027) </plain></SENT>
<SENT sid="5" pm="."><plain>Patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> younger than 60 years had significantly higher intensity of CD33 expression on CD34+ cells than patients 60 years or older </plain></SENT>
<SENT sid="6" pm="."><plain>Levels of CD33 intensity did not correlate with cytogenetics in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>There was no correlation between CD33 intensity and response to therapy or overall survival in 35 patients treated with protocols including Mylotarg </plain></SENT>
<SENT sid="8" pm="."><plain>These data demonstrate variation in CD33 intensity between various <z:hpo ids='HP_0001909'>leukemias</z:hpo> </plain></SENT>
</text></document>